Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.

@article{Zamboni2012BestPI,
  title={Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.},
  author={William Christopher Zamboni and Vladimir Torchilin and Anil K. Patri and Jeffrey S. Hrkach and Stephen T. Stern and Robert Lee and Andr{\'e} Nel and Nicholas J. Panaro and Piotr Grodzinski},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 12},
  pages={
          3229-41
        }
}
Historically, treatment of patients with cancer using chemotherapeutic agents has been associated with debilitating and systemic toxicities, poor bioavailability, and unfavorable pharmacokinetics. Nanotechnology-based drug delivery systems, on the other hand, can specifically target cancer cells while avoiding their healthy neighbors, avoid rapid clearance from the body, and be administered without toxic solvents. They hold immense potential in addressing all of these issues, which has hampered… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 57 CITATIONS, ESTIMATED Infinity% COVERAGE

57 Citations

051015'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 57 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 93 REFERENCES

SadriehN.Considerationswhen submitting nanotherapeutics to FDA/CDER for regulatory review

  • K Tyner
  • Methods Mol Biol
  • 2011
Highly Influential
3 Excerpts

Silver Spring (MD): U.S. Food and Drug Administration. FDA approval for doxorubicin hydrochloride liposome

  • R. Pazdur
  • Available from: http://www.cancer.gov…
  • 2012
2 Excerpts

Comparison of toxicity and study design issues of nanoparticle and small molecule anticancer agents in preclinical models and phase I clinical trials

  • K Morgan, CaronW, WalshM, B Zamboni, ZamboniW
  • Cancer Res
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…